HRSA Refers Boehringer Ingelheim to OIG Citing 340B Noncompliance
- April 01, 2022
The Health Resources & Services Administration (HRSA) has referred Boehringer Ingelheim Pharmaceuticals to the Department of Health and Human Services Office of Inspector General (OIG) for refusing to suspend certain policies the agency says restrict safety net hospitals’ access to discounts under the 340B program in violation of federal law.
ARTICLE TAGS
You must be logged in to access this content.